Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.
Megan E Daly, Charles B Simone, Mary W Redman et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3, multicentre, randomised controlled trial evaluated the addition of atezolizumab to stereotactic body radiation therapy (SBRT) in patients with high-risk, early-stage non-small-cell lung cancer (NSCLC). Among 402 eligible patients, the overall survival hazard ratio was 1.04 (95% CI 0.69-1.58), indicating no significant survival benefit from the combination therapy compared to SBRT alone, with both groups showing an estimated 2-year overall survival of 82%.
Key findings
- Overall survival hazard ratio was 1.04 (95% CI 0.69-1.58) with no significant difference.
- Estimated 2-year overall survival was 82% in both treatment groups.
- Grade 3 or higher adverse event rates were 12% with atezolizumab plus SBRT versus 3% with SBRT alone.
- Two grade 5 respiratory events occurred in the atezolizumab plus SBRT group.
Why it matters
The study highlights the lack of survival benefit from adding atezolizumab to SBRT in early-stage NSCLC, raising concerns about increased adverse events. Clinicians should consider these findings when discussing treatment options with patients.